VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Post-Operative Inflammation Following Cataract SurgeryWENZHOU, China and SAN DIEGO, Dec. 04, 2024 (GLOBE NEWSWIRE) -- VivaVision Biotech (VivaVision), a clinical-stage, privately held biotechnology company focused on developing treatments for ocular diseases, today announced positive topline results from its U.S. Phase 2 clinical trial of VVN461-CS-201, a potent non-steroidal dual JAK1/TYK2 immunomodulator for the treatment of post-operative inflammation following cataract surgery.
